198 related articles for article (PubMed ID: 31912365)
21. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.
Cazabat L; Bouligand J; Salenave S; Bernier M; Gaillard S; Parker F; Young J; Guiochon-Mantel A; Chanson P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E663-70. PubMed ID: 22319033
[TBL] [Abstract][Full Text] [Related]
22. Multimodal therapy in aggressive pituitary tumors.
Iglesias P; Magallón R; Mitjavila M; Rodríguez Berrocal V; Pian H; Díez JJ
Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(7):469-485. PubMed ID: 31740190
[TBL] [Abstract][Full Text] [Related]
23. Silent Crooke's cell corticotroph adenoma of the pituitary gland presenting as delayed puberty.
Giri D; Roncaroli F; Sinha A; Didi M; Senniappan S
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28458905
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.
Vicchio TM; Aliquò F; Ruggeri RM; Ragonese M; Giuffrida G; Cotta OR; Spagnolo F; Torre ML; Alibrandi A; Asmundo A; Angileri FF; Esposito F; Polito F; Oteri R; Aguennouz MH; Cannavò S; Ferraù F
J Endocrinol Invest; 2020 Jul; 43(7):947-958. PubMed ID: 31939196
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
26. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
27. Prognostic indicators in an aggressive pituitary Crooke's cell adenoma.
Kovacs K; Diep CC; Horvath E; Cusimano M; Smyth H; Lombardero CC; Scheithauer BW; Lloyd RV
Can J Neurol Sci; 2005 Nov; 32(4):540-5. PubMed ID: 16408589
[TBL] [Abstract][Full Text] [Related]
28. Aggressive pituitary tumors.
Chatzellis E; Alexandraki KI; Androulakis II; Kaltsas G
Neuroendocrinology; 2015; 101(2):87-104. PubMed ID: 25571935
[TBL] [Abstract][Full Text] [Related]
29. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis.
Cuny T; Pertuit M; Sahnoun-Fathallah M; Daly A; Occhi G; Odou MF; Tabarin A; Nunes ML; Delemer B; Rohmer V; Desailloud R; Kerlan V; Chabre O; Sadoul JL; Cogne M; Caron P; Cortet-Rudelli C; Lienhardt A; Raingeard I; Guedj AM; Brue T; Beckers A; Weryha G; Enjalbert A; Barlier A
Eur J Endocrinol; 2013 Apr; 168(4):533-41. PubMed ID: 23321498
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification.
Liu J; He Y; Zhang X; Yan X; Huang Y
Oncol Lett; 2020 Mar; 19(3):1890-1898. PubMed ID: 32194684
[TBL] [Abstract][Full Text] [Related]
32. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
[TBL] [Abstract][Full Text] [Related]
33. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
34. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
35. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
36. The clinical, pathological, and genetic features of familial isolated pituitary adenomas.
Beckers A; Daly AF
Eur J Endocrinol; 2007 Oct; 157(4):371-82. PubMed ID: 17893250
[TBL] [Abstract][Full Text] [Related]
37. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
38. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
39. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
